$UNCY Unicycive Announces Third Quarter 2024 Financial Results and Provides Business Update
– OLC New Drug Application (NDA) Accepted by the FDA with a PDUFA Target Action Date of June 28, 2025–

– Commercial Planning in Progress for 2025 Launch –

– Late Breaker Poster Presentation on OLC at ASN Kidney Week –

– Successful Completion of UNI-494 Phase 1 Trial –
https://finance.yahoo.com/news/unicycive-anno...00882.html

#nasdaq #stockstowatch #stockstobuy #UNCY @charles